Oxidative injury and stress responses are common features of many neurodegenerative diseases. To assess oxidative stress responses in frontotemporal lobar degeneration (FTLD), we identified increased 4-hydroxynonenal (HNE) adducts using gel electrophoresis and Western blotting in frontal cortex samples in 6 of 6 cases of FTLD with the P301L mutation in the tau gene (FTLD-tau), in 3 of 10 cases with tau-negative ubiquitin-immunoreactive inclusions, and in 2 of 3 cases associated with motor neuron disease. Selectively increased lipoxidation-derived protein damage associated with altered membrane unsaturation and fatty acid profiles was verified by mass spectrometry in FTLD-tau and FTLD associated with motor neuron disease. All FTLD-tau and most cases with increased HNEpositive bands had marked astrocytosis as determined by glial fibrillary acidic protein (GFAP) immunohistochemistry and increased GFAP expression on Western blotting; 2 FTLD cases with tau-negative ubiquitin-immunoreactive inclusions and with increased GFAP expression did not have increased HNE adducts. Bidimensional gel electrophoresis, Western blotting, in-gel digestion, and mass spectrometry identified GFAP as a major target of lipoxidation in all positive cases; confocal microscopy revealed colocalization of HNE and GFAP in cortical astrocytes, superoxide dismutase 1 in astrocytes, and superoxide dismutase 2 in astrocytes and neurons in all FTLD types. Thus, in FTLD, there is variable disease-dependent oxidative damage that is prominent in FTLD-tau, astrocytes are targets of oxidative damage, and GFAP is a target of lipoxidation. Astrocytes are, therefore, crucial elements of oxidative stress responses in FTLD.
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) designates a group of diseases having common progressive changes of personality and behavior, often with language impairment (i.e. frontotemporal dementia) associated with bilateral atrophy of the frontal and anterior temporal lobes. A prominent neuropathologic feature of FTLD is loss of neurons and microvacuolation that is mainly in the upper cortical layers and is accompanied by astrocytic gliosis. In addition to the frontal and temporal neocortex, the anterior cingulate gyrus, anterior insular cortex, hippocampus, entorhinal cortex, amygdala, and striatum (mainly the head of the caudate and putamen) are commonly affected. Loss of neurons and neuromelanin in macrophages, or free in the neuropil, can be present in the substantia nigra, even in cases with no apparent parkinsonian features (1Y7). The remaining neurons in the upper cortical layers have reduced numbers of dendrites and dendritic spines, and there is a loss of presynaptic markers. Glutamatergic projection neurons and calbindinimmunoreactive local-circuit neurons are equally affected. Because the upper cortical layers are the source of short cortico-cortical connections, involvement of these areas is dramatic evidence of the devastating effects of FTLD on cortical connectivity (8Y10).
The causes of frontotemporal dementia are varied. Three main groups of FTLD have been categorized, namely 1) tauopathies, including familial FTLD (and parkinsonism) linked to chromosome 17 because of mutations in the tau gene (MAPT 17q21-q22; FTLD-tau) (11Y17); 2) FTLD with tau-negative ubiquitin-positive inclusions (FTLD-U); and 3) FTLD with no distinctive neuropathologic features. The second group has been subdivided into different types depending on the localization, distribution, and predominance of ubiquitin inclusions in the nucleus, cytoplasm, and/or neuropil (7, 18Y20) . Most FTLD-U cases seem sporadic, but mutations in at least 3 genes may cause FTLD-U. They are the progranulin gene (PGRN) located 17q21-q22, charged multivesicular body protein 2B (CHMP2B) in 3p13-3p12, and valosin-containing protein gene (VCP) in 9q21-q22 (21Y28). In addition, FTLD with tau-negative ubiquitinpositive inclusions occurs in association with motor neuron disease and amyotrophic lateral sclerosis (FTLD-MND); linkage to chromosome 9 has been demonstrated in some of these cases (29, 30) . Frontotemporal lobar degeneration with tau-negative ubiquitin-positive neuronal inclusions (FTLD-U) is more common (50%) than FTLD with tau pathology (FTLDtau) (31) . The amount of new information that has accumulated in recent years has made it increasingly difficult to consider the third category (i.e. FTLD with no distinctive neuropathologic features) as a separate entity (32) .
Oxidative stress is common in degenerative diseases of the nervous system, including Alzheimer disease (33Y40). Oxidative damage has also been reported in several tauopathies (41Y43), but very little is known about oxidative stress in FTLD. Iron, in a redox-active state, is, however, increased in cases of frontotemporal dementia (44) .
In the present study, we investigate the presence of oxidative stress and its impact on common predominant proteins in FTLD-tau, FTLD-U, and FTLD-MND. For this purpose, the combination of single and double labeling immunofluorescence and confocal microscopy, monodimensional and bidimensional gel electrophoresis, Western blot analysis, in-gel digestion, and mass-spectrometry was used for the first time to analyze the frontal cortex in 19 FTLD cases (FTLD-tau, n = 6; FTLD-U, n = 10; FTLD-MND, n = 3) and compared with 10 age-matched controls. Subsequently, gas chromatography/mass spectrometry (GC/MS) analyses were performed to further dissect the molecular oxidative pathways by detecting and quantifying specific oxidation, glycoxidation, and lipoxidation-derived protein damage markers. Finally, to assess the role of structural components that can act as substrate targets in determining the cellular vulnerability, membrane fatty acid profiles and their degree of unsaturation were also measured. Because the first part of the study showed marked individual variations among FTLD-U cases, further attempts to delineate oxidative damage and lipid profiles were examined only in FTLD-U and FTLD-MND cases and controls.
MATERIALS AND METHODS

Cases
Patients were clinically categorized as having FTLD (16 cases) or FTLD + MND (3 cases). Clinical features of these patients are detailed elsewhere (45) . Age-matched controls (n = 10) had not had neurological or metabolic diseases.
The postmortem delay between death and tissue processing was between 3 and 15 hours; the bodies were maintained at 4-C. All cases were processed in the same way following the same sampling and staining protocols. At autopsy, half of each brain was fixed in 10% buffered formalin, whereas the other half was cut in 1-cm-thick coronal sections, frozen on dry ice, and stored at j80-C until use.
The neuropathologic study permitted the identification of 6 FTLD-tau (Cases 4Y6, 27Y29), 10 FTLD-U (Cases 7Y12, 23Y26), and 3 FTLD-MND (Cases 13Y15). Genetic studies demonstrated the P301L mutation in the 6 FTLD-tau cases, and the c908delC and P357HfsX3 mutations in the progranulin gene in 2 FTLD-U cases (Cases 10 and 26, respectively). The neuropathologic examination was normal in the 10 control cases, including lack of neurofibrillary tangles and amyloid deposits in any region, except a few diffuse plaques in the temporal and orbital cortex in two. The cases are summarized in Table 1 .
Double Labeling Immunofluorescence and Confocal Microscopy
Dewaxed 5-Km-thick sections were stained with a saturated solution of Sudan black B (Merck, Barcelona, Spain) for 10 minutes to block the autofluorescence of lipofuscin granules present in nerve cell bodies; they were then rinsed in 70% ethanol and washed in distilled water. The sections were incubated at 4-C overnight with a combination of the primary antibodies to glial fibrillary acidic protein (GFAP) and 4-hydroxynonenal (HNE) or superoxide dismutase 1 (SOD1) or superoxide dismutase 2 (SOD2) diluted in PBS. Monoclonal anti-GFAP antibody or rabbit anti-GFAP antibody (Dako, Barcelona, Spain) were used at a dilution of 1:250; rabbit polyclonal anti-HNE antibody (Calbiochem, Barcelona, Spain) was used at a dilution of 1:50; monoclonal anti-SOD1 antibody was used at dilution 1:50 (Novocastra, Servicios Hospitalarios, Barcelona, Spain), and rabbit anti-SOD2 was diluted at 1:100 (Stressgen, Bionova, Madrid, Spain).
After washing in PBS, the sections were incubated in the dark for 45 minutes at room temperature with the cocktail of secondary antibodies diluted in the same vehicle solution as the primary antibodies. Secondary antibodies were Alexa488 anti-rabbit and Alexa546 anti-mouse immunoglobulin (both from Molecular Probes, Leiden, Netherlands). These were used at a dilution of 1:400. Nuclei were stained with TO-PRO-3-iodide (Molecular Probes) diluted 1:1000. Some sections were incubated only with the secondary antibodies; these sections were considered as negative controls. Sections were examined with a Leica TCS-SL confocal microscope.
Gel Electrophoresis and Western Blotting
Brain samples (weighing 0.1 g) of the frontal cortex from control, FTLD-tau, FTLD-U, and FTLD-MND cases were homogenized in 1 mL of lysis buffer (20 mmol/L TrisHCl pH 7.4, 7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 1 mmol/L sodium orthovanadate, and complete protease inhibitor cocktail [Roche Molecular Systems, Barcelona, Spain]) and centrifuged at 5,000 rpm for 10 minutes at 4-C. The pellets were discarded, and protein concentrations of the supernatants were determined by the Bradford method with bovine serum albumin (Sigma, Barcelona, Spain) as a standard. Samples containing 30 Kg of protein were loaded onto 10% acrylamide gels, and proteins were separated by sodium dodecyl sulfateYpolyacrylamide gel electrophoresis and then transferred to nitrocellulose membranes (200 mA/gel for 90 minutes). The membranes were then blocked with 5% skim milk in TBS-T buffer (100 mmol/L Tris-buffered saline, 140 mmol/L NaCl, and 0.1% Tween 20, pH 7.4) for 1 hour at room temperature and incubated with the primary antibody in TBS-TY3% bovine serum albumin at 4-C overnight. After the incubation and washes with TBS, the membranes were blocked with 5% skim milk in TBS-T buffer and then incubated with rabbit polyclonal anti-HNE antibody (Calbiochem) at a dilution of 1:1000, rabbit polyclonal anti-catalase (Calbiochem) diluted 1:6000, rabbit polyclonal anti-GFAP (Dako) diluted 1:500, or mouse monoclonal anti-GFAP antibody (Dako) used at a dilution of 1:10000. Later, the membranes were washed 3 times in TBS-T for 5 minutes and then incubated for 45 minutes at room temperature, with the corresponding secondary antibody labeled with horseradish peroxidase (Dako) at a dilution of 1:1000 and washed in TBS-T for 30 minutes. The immunoreactivity was detected with the chemiluminescence ECL method (Amersham, Barcelona, Spain). The monoclonal antibody to A-actin (Sigma) was used at a dilution of 1:10000 as a control of protein loading.
Two-Dimensional Gel Electrophoresis
In the first dimension electrophoresis, samples were applied onto a 7-cm 4 to 7 pH nonlinear gradient ReadyStrip immobilized pH gradient strip (Bio-Rad, Barcelona, Spain) for isoelectric focusing. The strips were actively rehydrated at 50 V for 12 hours, and the proteins were focused at 500 V for 1 hour, after which the voltage was gradually increased to 1000 V for 1 hour. Focusing was increased to 8,000 V for 1 hour more, and the voltage was continued at 8,000 V for 10 hours. After focusing, the isoelectric focusing strips were stored at j80-C until the second dimension electrophoresis was performed.
For the second dimension electrophoresis, immobilized pH gradient strips were equilibrated for 10 minutes in 50 mmol/L Tris-HCl (pH 6.8) containing 6 mol/L urea, 1% (wt/vol) sodium dodecyl sulfate, 30% (vol/vol) glycerol, and 2% dithiothreitol, and next re-equilibrated for 10 minutes in the same buffer containing 2.5% iodoacetamide. The strips were placed on 10% polyacrylamide gels together with standards (Fermentas, Ontario, Canada). For the second dimension, 2 gels from the same case were run in parallel. One replicate was stained with Coomassie blue (Bio-Rad), and the other replicate was transferred to a nitrocellulose membrane (200 mA/gel for 90 minutes). Transferred nitrocellulose membranes were processed for blotting. After incubation with 5% skim milk in TBS-T buffer for 1 hour at room temperature, nitrocellulose membranes were incubated with rabbit anti-HNE (Calbiochem), previously incubated with NaBH4 10 mmol/L in TBS, used at dilution of 1:1000. Membranes were also incubated with monoclonal anti-GFAP antibody (Dako) used at dilution of 1:10000. The immunoreactions were visualized as previously described (39) .
In-Gel Digestion
Proteins were in-gel digested with trypsin (Promega, Barcelona, Spain) in the automatic Investigator ProGest robot of Genomic Solutions (Isogen Life Science, Barcelona, Spain). Briefly, excised gel spots were washed sequentially with ammonium bicarbonate buffer and acetonitrile. Proteins were reduced with 10 mmol/L dithiothreitol solution during 30 minutes and alkylated with 100 mmol/L solution of iodine acetamide. After sequential washings with buffer and acetonitrile, proteins were digested overnight at 37-C with trypsin 0.27 nmol/L. Tryptic peptides were extracted from the gel matrix with 10% formic acid and acetonitrile. The extracts were pooled and dried in a vacuum centrifuge.
Acquisition of MS and MS/MS Spectra
Proteins manually excised from the 2-dimensional (2-D) gels were digested and analyzed by CapLC-nano-ESI-MS-MS. The tryptic digested peptide samples were analyzed using an online liquid chromatography (CapLC, MicromassWaters, Manchester, United Kingdom) coupled to a tandem MS (Q-TOF Global, Micromass-Waters) (43) . Data were There is a clear relationship between astrocyte numbers, GFAP protein expression levels, and HNE expression levels in every case, with the exception of Case 11, in which increased GFAP expression is accompanied by moderate increase in HNE expression levels.
CTL, control; FTLD-MND, frontotemporal lobar dementia with tau-negative ubiquitin-positive inclusions that occurs in association with motor neuron disease and amyotrophic lateral sclerosis; FTLD-tau, frontotemporal lobar dementia with tau pathology; FTLD-U, frontotemporal lobar degeneration with tau-negative ubiquitinpositive neuronal inclusions; GFAP, glial fibrillary acidic protein; HNE, 4-hydroxynonenal. generated in PKL file format and submitted for database searching in MASCOT server (Matrix Science, Boston, MA) using the National Center for Biotechnology Information database with the following parameters: trypsin enzyme, 1 missed cleavage, carbamidomethyl (C) as fixed modification and oxized (M) as variable modification, and mass tolerance of 150 to 250 ppm.
Probability-based MOWSE score was used to determine the level of confidence in the identification of specific isoforms from the mass spectra. This probability equals 10
(jMowse score/10) . Mowse scores greater than 50 were considered to be of high confidence of identification.
GC/MS Analyses of Protein Damage
The markers measured were, for protein oxidation: glutamic semialdehyde (GSA) and aminoadipic semialdehyde (AASA), which are specific protein carbonyls; for glycoxidation: N?-(carboxyethyl)lysine (CEL); for mixed glycoxidation and lipoxidation: N?-(carboxymethyl)lysine (CML); and for lipoxidation: N?-(malondialdehyde)lysine (MDAL). The GSA, AASA, CML, CEL, and MDAL were determined as trifluoroacetic acid methyl ester derivatives in acid hydrolyzed delipidated and reduced protein samples by GC/ MS (46) using an HP6890 Series II gas chromatograph (Agilent, Barcelona, Spain) with a MSD5973A Series and a 7683 Series automatic injector, an HP-5MS column (30 m Â 0.25 mm Â 0.25 Km), and the described temperature program (39) . Quantification was performed by internal and external standardization using standard curves constructed from mixtures of deuterated and nondeuterated standards.
GC/MS Analyses of Membrane Fatty Acid Profile
Fatty acyl groups of human frontal cortex lipids were analyzed as methyl ester derivatives by GC/MS as previously described (39) 
RESULTS
General Neuropathologic Findings
Variable degrees of neuron loss, spongiosis in the upper cellular layers, and reactive astrocytosis were present in every FTLD case, and characteristic inclusions were present in every FTLD type (Fig. 1) . Cases with FTDLtau showed tau-immunoreactive neurons and fewer tauimmunoreactive astrocytes (Fig. 1C) . Cases with FTLD-U showed ubiquitin-immunoreactive intraneuronal inclusions and neurites (Fig. 1F) ; cases affected by FTLD-MND had globular ubiquitin-immunoreactive neuronal cytoplasmic inclusions (Fig. 1I) . The 2 cases with mutation in the progranulin gene had characteristic cat eyeYshaped intranuclear inclusions. All FTLD-U and FTLD-MND cases had TDP-43Yimmunoreactive inclusions.
The degrees of neuron loss and astrocytosis in the frontal cortex in FTLD and control cases were assessed in a semiquantitative manner and are summarized in Table 2 .
Gel Electrophoresis and Western Blotting to GFAP and HNE in Controls
Monodimensional gel electrophoresis and GFAP Western blotting of the frontal cortex revealed a band of approximately 50 kd and a weaker band of approximately 40 kd in most control cases (Fig. 2) . Increased GFAP immunoreactivity was seen in a single case (Case 2; see later). Monodimensional gel electrophoresis to HNE showed 2 bands of approximately 50 and 40 kd in most cases (Fig. 2) , with the exception of moderate HNE immunoreactivity in Case 2. One case showed an apparent absence of GFAP and HNE immunoreactivity, but typical bands in this case were detected with a long time of exposure (data not shown).
Gel Electrophoresis and Western Blotting to GFAP and HNE in Pathological Cases
Monodimensional gel electrophoresis and GFAP Western blotting of the frontal cortex revealed several bands of strong GFAP immunoreactivity between 35 and 50 kd in (Fig. 3) . One control case (Case 2) had moderate GFAP immunoreactivity. Similar findings were obtained using mouse monoclonal and rabbit polyclonal anti-GFAP antibodies (Fig. 3) . The intensity of GFAP immunoreactivity, as revealed in Western blot analysis, correlated with the amount of cortical GFAP-immunoreactive astrocytes identified by immunohistochemistry (Table 2) .
Monodimensional gel electrophoresis and Western blot analysis of HNE revealed higher intensities of bands between 35 and 50 kd in some pathological cases than in controls. Increased densities of HNE bands were observed in the 6 FTLD-tau cases (Cases 4Y6, 27Y29), 3 of 10 FTLD-U cases (Cases 10, 12, 23), and 2 FTLD-MND cases (Cases 14, 15) (Fig. 4) . Increased density of the upper band was noticed in another FTLD-U (Case 11). A moderate increase in HNE expression was present in 1 control (Case 2) (Fig. 4) . The intensity of HNE-immunoreactive bands expressed semiquantitatively is shown in Table 2 for comparison to other morphological and biochemical parameters.
2-D Gel Electrophoresis, In-Gel Digestion, and MS
4-Hydroxynonenal antibody was used in Western blots of 2-D gels. Control (Cases 1Y3) and FTLD cases (Cases 4Y6, 10, 12, 14, 15) were processed in parallel on different days. Several spots between 65 and 70 kd appeared in some FTLD cases, thus indicating that different proteins could be targets of lipoxidation in FTLD. However, only spots between 35 and 50 kd that were consistently present in HNEpositive cases were selected for study.
Corresponding Coomassie-stained spots were excised from Cases 4, 10, 12, 14, and 15, in-gel digested, and processed for MS. All spots were identified as GFAP as primary or unique option with Mowse scores of high confidence (Table 3) . Other spots also appeared in individual cases, suggesting that other proteins were targets of oxidation, but because these spots were neither consistent nor related to age, sex, or pathology, no further attempts were made to identify them.
Validation
Parallel membranes were blotted with anti-HNE and anti-GFAP antibodies in control and FTLD cases. Spots of FTLD-tau, FTLD-U Cases 10 and 12, and FTLD-MND Cases 14 and 15 stained with anti-HNE antibody matched with spots incubated with anti-GFAP antibodies (Figs. 5Y7).
Double Labeling Immunofluorescence and Confocal Microscopy
Sections of the frontal cortex in controls and in Cases 4 to 6 (FTLD-tau), 10, 12 (FTLD-U), 14, and 15 (FTLD-MND) were double stained with anti-HNE and anti-GFAP. This analysis demonstrated colocalization of these antibodies in reactive astrocytes in FTLD (Fig. 8 ). Neurons were not stained with anti-HNE antibodies. Double labeling with antibodies to GFAP and SOD1 demonstrated the presence of SOD1 in astrocytes in FTLD-tau and FTLD-U cases (Fig. 9) , whereas double labeling immunofluorescence and confocal FTLD-MND, frontotemporal lobar dementia with tau-negative ubiquitin-positive inclusions that occurs in association with motor neuron disease and amyotrophic lateral sclerosis; FTLD-tau, frontotemporal lobar dementia with tau pathology; FTLD-U, frontotemporal lobar degeneration with tau-negative ubiquitin-positive neuronal inclusions; GFAP, glial fibrillary acidic protein; GI, genInfo identification number; pI, isoelectric point. microscopy showed SOD2 in reactive astrocytes and neurons (Fig. 10) .
Catalase Expression
Western blot analysis of catalase in the frontal cortex in control and FTLD cases demonstrated increased catalase expression levels that largely correlated with other oxidative stress responses in individual cases (Fig. 11) .
GC/MS Analysis of Protein Damage
Because of individual variations in the FTLD-U group, GC/MS analysis of protein damage and fatty acid profile was carried out only in FTLD-tau and FTLD-MND. The steadystate levels of representative specific markers of protein oxidation (GSA and AASA), glycoxidation (CEL and CML), and lipoxidation (MDAL) are shown in Table 4 and Figure 12 . The MDAL was the most sensitive marker for the presence of disease because it showed significantly higher values both in FTLD-tau and FTLD-MND cases compared with the controls. The CML exhibited slightly but not significantly higher values both in FTLD-tau and in FTLD-MND compared with the controls. The CEL levels were significantly higher in FTLD-tau, but not in FTLD-MND, compared with the control group. Finally, protein oxidation markers showed significantly higher values in FTLD-tau and significantly lower values in FTLD-MND compared with the controls.
GC/MS Analysis of Fatty Acid Profile
The full fatty acid composition of frontal cortex and derived indices are shown in Table 5 . The FTLD-tau significantly increased 16:1n-7 and 18:1n-9 and decreased 18:0, 18:3n-3, and 22:6n-3 compared with the controls. The FTLD-MND significantly increased 18:1n-9 and 20:4n-6, and decreased 18:3n-3, 22:0, 22:4n-6, and 22:6n-3 compared with the control group. These changes in membrane fatty acid profile resulted in lowered saturated fatty acids and polyunsaturated fatty acids (PUFAs) (specifically PUFAn-3) contents, as well as double bond and peroxidizability indices, and increased monounsaturated fatty acid content in FTLDtau than in the control group. In contrast, FTLD-MND only resulted in significantly lowered PUFAn-3 content and increased PUFAn-6. Double bond and peroxidizability indices were lower, but not significantly, in FTLD-MND compared with the control group. 
DISCUSSION
Using anti-HNE antibodies and MS, we demonstrate increased lipoxidative damage in the frontal cortex in cases of FTLD. Frontotemporal lobar degeneration is not a single disorder, however, and there were marked differences in the extent of oxidative damage among the different types of FTLD. Increased lipoxidative damage was present in all 6 FTLD-tau cases, but only in 3 of 10 FTLD-U and in 2 of 3 FTLD-MND cases. Therefore, the oxidative damage is probably not the result of a single molecular event among the different FTLD types.
The brain consumes a large proportion of total oxygen used by the body; it is rich in PUFAs and low in antioxidant components. It has, therefore, a particularly high vulnerability to oxidative stress (36) . Polyunsaturated fatty acids can be attacked by oxidative injury mechanisms that lead to the formation of reactive species, including HNE and MDA among others (40, 47) . These species are produced during lipid peroxidation and react with nucleophilic side chains of Cys, His, and Lys residues, thereby generating covalent unions between aldehyde carbonyl groups and peptide chains. This promotes protein lipoxidative damage, loss of function, and cell death (48Y50). Lipoxidative damage is further enhanced when there is impaired mitochondrial function. With these premises and reinforcing the findings previously described, significantly increased lipoxidationderived protein damage was verified by GC/MS in FTLD cases. This molecular injury seems to be linked with increased lipoxidative damage at the cellular level, which in turn, is associated with profound changes in membrane unsaturation and fatty acid profile, particularly in FTLD-tau. Moreover, the available data suggest striking biochemical differences between FTLD-tau and FTLD-MND cases as evidenced by disease-specific patterns of subtypes of protein oxidative damage and fatty acid composition.
Proteomic studies focusing on FTLD-tau have shown increased GFAP (5.4-fold change) and increased SOD2 (11.2-fold change), among other modifications (51) . These changes, of upregulation of GFAP and oxidative stress responses, parallel the present observations in FTLD-tau. Proteomic and functional studies in transgenic mice bearing the P301L FIGURE 11 . Western blots to catalase in the frontal cortex in control and frontotemporal lobar dementia (FTLD) cases. Increased expression levels are found in the 6 cases with FTLD with tau pathology (FTLD-tau), in 2 of 3 FTLD with taunegative ubiquitin-positive inclusions that occurs in association with motor neuron disease and amyotrophic lateral sclerosis (FTLD-MND) cases, and in FTLD with tau-negative ubiquitinpositive neuronal inclusions (FTLD-U) cases with oxidative damage (see Fig. 4 for comparison) . CTL, control case. ACL, average chain length; SFA, saturated fatty acid; UFA, unsaturated fatty acid; MFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid; DBI, double bond index; FTLD-MND, frontotemporal lobar dementia with tau-negative ubiquitin-positive inclusions that occurs in association with motor neuron disease and amyotrophic lateral sclerosis; FTLD-tau, frontotemporal lobar dementia with tau pathology; FTLD-U, frontotemporal lobar degeneration with tau-negative ubiquitin-positive neuronal inclusions. mutation in the tau gene have also shown reduced NADHubiquinone oxireductase activity, reduced mitochondrial respiration, and reduced adenosine triphosphate synthase, together with increased reactive oxygen species, elevated antioxidant enzymes, enhanced SOD and glutathione reductase activities, and lowered in vivo lipoxidation and increased in vitro lipoxidation, as estimated by MDA levels (52) . In light of the present findings, this last observation is likely caused by a lower membrane unsaturation in P301L mutants. Despite that the origin of this change in membrane unsaturation is unknown, it is likely caused by the combined effect of different factors, including 1) changes in cellular populations (neuronal loss and astrocytosis) with cell-specific fatty acid profiles, 2) alterations in metabolic pathways where specific fatty acids (particularly 22:6n-3) participate, 3) cellular membrane adaptations to the pathological state, and 4) the flux of oxidative damage directed to the cellular membrane.
No similar studies have been performed in FTLD-U, and no available models of FTLD-U are currently available. Recent studies have, however, shown a link between oxidative stress, oxidative damage, mitochondrial abnormalities, and endoplasmic reticulum stress in the spinal cord in patients with amyotrophic lateral sclerosis (53) . For these reasons, despite being a neuropathologic variety of FTLD-U, the FTLD-MND cases in the present study have been considered apart. Because of the limited number of cases and considering that causes of oxidative damage in FTLD-MND may differ from those of other FTLD-U cases, further studies are necessary to probe specific impairment of metabolic pathways in FTLD-MND compared with other FTLD-U cases.
With the exception of 2 cases in which GFAP expression levels were higher than those corresponding to HNE, the intensity of oxidative damage correlated with astrocytosis ascertained by GFAP immunohistochemistry in the adjacent cortex and by levels of GFAP protein expression as revealed by Western blot analysis of total cortex homogenates. Bidimensional gel electrophoresis, Western blotting to HNE, in-gel digestion, and MS revealed GFAP as the first or unique candidate in every individually analyzed spot from FTLD-tau, FTLD-U, and FTLD-MND cases. Additional spots were also observed in individual cases, thus suggesting that other proteins may be additional targets of lipoxidation. Because of the extreme variability among cases, however, no further attempts were made to characterize these additional spots. Finally, double labeling immunofluorescence and confocal microscopy revealed the presence of HNE and SOD1 only in reactive cortical astrocytes in FTLD cases and SOD2 in neurons and astrocytes. Increased expression levels of catalase that correlated with oxidative damage were also demonstrated in Western blots of total frontal cortex homogenates.
Previous studies have shown GFAP to be a target of oxidation in Alzheimer disease (39, 54) and certain tauopathies such as Pick disease (46) and progressive supranuclear palsy (55) . Glial fibrillary acidic protein oxidation has, however, also been reported in conditions not associated with tau pathology, such as aceruloplasminemia (56) , diabetic retina (57) , and Huntington disease (58) . The present observations also indicate that although prominent GFAP lipoxidative damage occurs in FTLD-tau, GFAP is also involved in FTLD cases without tau pathology, including FTLD-U and FTLD-MND. On the other hand, not all FTLD-U cases with increased GFAP have similarly increased expression of HNE adducts.
In summary, disease-specific oxidative damage and fatty acid patterns seem to underlie different FTLD subtypes; these are particularly pronounced in FTLD-tau cases. Furthermore, the present findings show astrocytes as targets of lipoxidative damage, GFAP as a target of lipoxidation, and that astrocytes are crucial elements of oxidative stress responses in FTLD. Further work is needed to elucidate common and specific pathological metabolic pathways in FTLD-tau, FTLD-U, and FTLD-MND.
